{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octreotide+Acetate",
    "query": {
      "intervention": "Octreotide Acetate"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 126,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octreotide+Acetate&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T21:17:38.756Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00884715",
      "title": "Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoid Syndrome"
      ],
      "interventions": [
        {
          "name": "Octreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endo USA Inc., a Keenova Therapeutics Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 10,
      "start_date": "2009-07",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 3,
      "location_summary": "Iowa City, Iowa • Boston, Massachusetts • Burlington, Massachusetts",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Burlington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00884715"
    },
    {
      "nct_id": "NCT05361668",
      "title": "Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoid Syndrome",
        "Carcinoid",
        "Carcinoid Tumor",
        "Carcinoid Tumor of Ileum",
        "Carcinoid Tumor of Cecum",
        "Carcinoid Syndrome Diarrhea",
        "Carcinoid Intestine Tumor",
        "Carcinoid Tumor of Liver",
        "Carcinoid Tumor of Pancreas"
      ],
      "interventions": [
        {
          "name": "Randomized: 40 mg Paltusotine",
          "type": "DRUG"
        },
        {
          "name": "Randomized: 80 mg Paltusotine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Crinetics Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2022-04-22",
      "completion_date": "2026-02-24",
      "has_results": true,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Newport Beach, California • Stanford, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05361668"
    },
    {
      "nct_id": "NCT00002864",
      "title": "Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "octreotide acetate",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NCIC Clinical Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "Up to 120 Years · Female only"
      },
      "enrollment_count": 667,
      "start_date": "1996-09-24",
      "completion_date": "2010-04-23",
      "has_results": false,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 2,
      "location_summary": "Duluth, Minnesota",
      "locations": [
        {
          "city": "Duluth",
          "state": "Minnesota"
        },
        {
          "city": "Duluth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002864"
    },
    {
      "nct_id": "NCT00426153",
      "title": "Octreotide in Severe Polycystic Liver Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Polycystic Kidney, Autosomal Dominant",
        "Polycystic Liver Disease",
        "Hepatomegaly",
        "Liver Diseases",
        "Kidney, Polycystic",
        "Abdominal Pain"
      ],
      "interventions": [
        {
          "name": "Octreotide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 42,
      "start_date": "2007-01",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2012-11-21",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426153"
    },
    {
      "nct_id": "NCT06592261",
      "title": "Graded Insulin Suppression Test P&F",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Resistance",
        "Hyperinsulinemia",
        "Obesity",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)",
          "type": "DRUG"
        },
        {
          "name": "Insulin regular, 32 mU/m2/min (hyperinsulinemia)",
          "type": "DRUG"
        },
        {
          "name": "Octreotide Acetate, 6-45 ng/kg/min",
          "type": "DRUG"
        },
        {
          "name": "Dextrose 20 % in Water",
          "type": "DRUG"
        },
        {
          "name": "Glucagon, 0-0.5 ng/kg/min",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2024-09-16",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06592261"
    },
    {
      "nct_id": "NCT00002779",
      "title": "Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "octreotide acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "1998-02",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-12-15",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002779"
    },
    {
      "nct_id": "NCT03972488",
      "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastro-enteropancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Lutathera",
          "type": "DRUG"
        },
        {
          "name": "30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)",
          "type": "DRUG"
        },
        {
          "name": "2.5% Lys-Arg sterile amino acid solution",
          "type": "DRUG"
        },
        {
          "name": "High dose 60 mg octreotide long-acting repeatable",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanced Accelerator Applications",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 226,
      "start_date": "2020-01-08",
      "completion_date": "2027-10-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972488"
    },
    {
      "nct_id": "NCT01412424",
      "title": "Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acromegaly"
      ],
      "interventions": [
        {
          "name": "Octreotide capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiasma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 155,
      "start_date": "2012-03",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01412424"
    },
    {
      "nct_id": "NCT06126354",
      "title": "Dexamethasone/Pancreatic Clamp P&F",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Resistance",
        "Prediabetic State",
        "Non-Alcoholic Fatty Liver Disease",
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Insulin human",
          "type": "DRUG"
        },
        {
          "name": "Octreotide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Glucagon",
          "type": "DRUG"
        },
        {
          "name": "Human Growth Hormone",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone Oral",
          "type": "DRUG"
        },
        {
          "name": "[6,6-2H2] D-glucose",
          "type": "OTHER"
        },
        {
          "name": "20% D-glucose (aq)",
          "type": "DRUG"
        },
        {
          "name": "BOOST Plus",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Harvard Apparatus PHD ULTRA CP syringe pump",
          "type": "DEVICE"
        },
        {
          "name": "Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer",
          "type": "DEVICE"
        },
        {
          "name": "Normal saline",
          "type": "OTHER"
        },
        {
          "name": "Human albumin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIETARY_SUPPLEMENT",
        "DEVICE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-07-01",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06126354"
    },
    {
      "nct_id": "NCT03197012",
      "title": "Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "90Y-DOTA-TOC",
          "type": "DRUG"
        },
        {
          "name": "68Ga-DOTA-TOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Hope",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-07-01",
      "completion_date": "2019-05-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-09-02T21:17:38.756Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03197012"
    }
  ]
}